We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New Insight into Structural Mechanism of Coronavirus Receptor Binding to Aid Development of COVID-19 Treatments and Vaccines

By HospiMedica International staff writers
Posted on 18 Sep 2020
Image: New Insight into Structural Mechanism of Coronavirus Receptor Binding to Aid Development of COVID-19 Treatments and Vaccines (Photo courtesy of Francis Crick Institute)
Image: New Insight into Structural Mechanism of Coronavirus Receptor Binding to Aid Development of COVID-19 Treatments and Vaccines (Photo courtesy of Francis Crick Institute)
New insight into the mechanism of infection of the SARS-CoV-2 coronavirus could equip research groups with the understanding needed to inform studies into COVID-19 vaccines and treatments.

The surface of SARS-CoV-2, the virus that causes COVID-19, is covered in proteins called spikes, which enable the virus to infect human cells. The infection begins when a spike protein binds with ACE2 cell surface receptors and, at later stages, catalyses the release of the virus genome into the cell. However, the exact nature of the ACE2 binding to the SARS-CoV-2 spike remains unknown. Researchers from the Francis Crick Institute (London, UK) have now found that the spike protein on the surface of the SARS-CoV-2 coronavirus can adopt at least 10 distinct structural states, when in contact with the human virus receptor ACE2.

In the first study to examine the binding mechanism between ACE2 and the spike protein in its entirety, the researchers have characterized 10 distinct structures that are associated with different stages of receptor binding and infection. The team incubated a mixture of spike protein and ACE2 before trapping different forms of the protein by rapid freezing in liquid ethane. They examined these samples using cryo-electron microscopy, obtaining tens of thousands of high-resolution images of the different binding stages. They observed that the spike protein exists as a mixture of closed and open structures., Following ACE2 binding at a single open site, the spike protein becomes more open, leading to a series of favorable conformational changes, priming it for additional binding. Once the spike is bound to ACE2 at all three of its binding sites, its central core becomes exposed, which may help the virus to fuse to the cell membrane, permitting infection. The researchers hope that the more they can uncover about how SARS-CoV-2 differs from other coronaviruses, the more targeted they can be with the development of new treatments and vaccines. The team continues to examine the structures of spikes of SARS-CoV-2 and related coronaviruses in other species to better understand the mechanisms of viral infection and evolution.

“As we unravel the mechanism of the earliest stages of infection, we could expose new targets for treatments or understand which currently available anti-viral treatments are more likely to work,” said Antoni Wrobel, co-lead author and postdoctoral training fellow in the Structural Biology of Disease Processes Laboratory at the Crick.

“There’s so much we still don’t know about SARS-CoV-2, but its basic biology contains the clues to managing this pandemic,” said Steve Gamblin, group leader of the Structural Biology of Disease Processes Laboratory at the Crick. “By understanding what makes this virus distinctive, researchers could expose weaknesses to exploit.”

Related Links:
Francis Crick Institute

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
MRI System
nanoScan MRI 3T/7T

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more